Tenaya holder plans sale of 1.59M shares

Tenaya Therapeutics, Inc. (TNYA) shareholder has filed a notice of proposed sale under Rule 144 for 1,591,090 shares of common stock.

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. (TNYA) shareholder has filed a notice of proposed sale under Rule 144 for 1,591,090 shares of common stock. The shares are to be sold through BTIG, LLC on or around February 10, 2026 on the NASDAQ.

The filing lists an aggregate market value of $1,256,960.80 for the proposed sale and notes that 213,744,535 shares of common stock were outstanding. The shares being sold were originally acquired in Series A financing transactions in 2016 and 2017 for cash.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Tenaya Therapeutics (TNYA) Form 144 filing disclose?

The filing discloses that a Tenaya Therapeutics shareholder plans to sell 1,591,090 shares of common stock under Rule 144. The proposed sale has an aggregate market value of $1,256,960.80 and is expected to occur on or about February 10, 2026.

How many Tenaya Therapeutics (TNYA) shares are proposed to be sold and through which broker?

The shareholder intends to sell 1,591,090 common shares of Tenaya Therapeutics. The filing states that the transaction will be handled by broker BTIG, LLC, located in San Francisco, with the shares expected to trade on the NASDAQ exchange.

What is the reported market value of the Tenaya Therapeutics (TNYA) shares in this Form 144?

The Form 144 lists an aggregate market value of $1,256,960.80 for the 1,591,090 common shares to be sold. This figure reflects the market valuation used for the notice and provides a dollar scale for the planned Rule 144 sale.

When were the Tenaya Therapeutics (TNYA) shares being sold originally acquired?

According to the filing, the common shares were acquired in Series A financing transactions on October 13, 2016 and July 31, 2017. The consideration for these acquisitions was paid in cash, as specified in the acquisition information table.

How many Tenaya Therapeutics (TNYA) shares were outstanding in this Form 144?

The notice reports that 213,744,535 shares of common stock were outstanding. This figure provides context for the size of the proposed 1,591,090-share sale relative to the overall share count of Tenaya Therapeutics at the time of the filing.

On which exchange will the Tenaya Therapeutics (TNYA) Form 144 shares be sold and when?

The filing indicates the common shares are expected to be sold on the NASDAQ exchange. The approximate date of sale is listed as February 10, 2026, reflecting when the shareholder anticipates executing the Rule 144 transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 05:25 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001668085
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tenaya Therapeutics, Inc.
SEC File Number	001-40656
Address of Issuer	171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	415-865-2066
Name of Person for Whose Account the Securities are To Be Sold	COLUMN GROUP III-A, LP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	BTIG, LLC 350 Bush Street, 9th floor San Francisco CA 94104	1591090	1256960.80	213744535	02/10/2026	NASDAQ GS

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/13/2016	Series A financing	Tenaya Therapeutics			28728	10/13/2016	Cash
Common	10/13/2016	Series A financing	Tenaya Therapeutics			843638	10/13/2016	Cash
Common	07/31/2017	Series A financing	Tenaya Therapeutics			718724	07/31/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	James Evangelista
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)